Welcome to the forefront of conversational AI as we explore the fascinating world of AI chatbots in our dedicated blog series. Discover the latest advancements, applications, and strategies that propel the evolution of chatbot technology. From enhancing customer interactions to streamlining business processes, these articles delve into the innovative ways artificial intelligence is shaping the landscape of automated conversational agents. Whether you’re a business owner, developer, or simply intrigued by the future of interactive technology, join us on this journey to unravel the transformative power and endless possibilities of AI chatbots.
Something went wrong
We just covered the Claude Stock Portfolio: Top 10 Stocks to Buy According to AI Chatbot. Eli Lilly and Company (NYSE:LLY) ranks #2 (see Claude Stock Portfolio: Top 5 Stocks to Buy According to AI Chatbot).
Number of Hedge Funds: 137
Eli Lilly and Company (NYSE:LLY) is among the top stock picks of the Claude AI chatbot in 2026. It likes Eli Lilly and Company because it believes the company has stronger long-term advantages in the obesity drug market. It said Eli Lilly and Company (NYSE:LLY) controls about 60% of the U.S. obesity-drug market, while Novo Nordisk, despite being the cheaper stock, is losing market share and posted negative revenue growth. Claude also highlighted that Lilly has a U.S. trade and tariff exemption through January 2029 that Novo does not have. In addition, it believes Eli Lilly and Company (NYSE:LLY) has a stronger pipeline of future drugs, including oral GLP-1 treatments, and better upcoming trial readouts.
Baron Health Care Fund stated the following regarding Eli Lilly and Company (NYSE:LLY) in its Q1 2026 investor letter:
“Eli Lilly and Company (NYSE:LLY), a global pharmaceutical company currently best known for its GLP-1 treatments for diabetes and obesity, detracted from performance. Longer term, we continue to view Lilly’s Mounjaro and Zepbound, along with its oral GLP-1 orforglipron, as best-in-class treatment options for diabetic and obese patients. We expect…. (Click Here to Read the Letter in Detail).”
While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
Sign in to access your portfolio
